Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.77 |
| ▸ | PPARG | P37231 | 4/20 | 0.77 |
| ▸ | FABP2 | P12104 | 2/20 | 0.77 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9372364 | 0.91 | PPARA (0.72) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL21351478 | 0.87 | PPARA (0.72) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL822492 | 0.87 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL16377 | 0.87 | PPARA (1.00) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL11161555 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL10967778 | 0.85 | PPARA (0.97) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL16577214 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL28478335 | 0.85 | PPARA (0.97) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL12634744 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL16580096 | 0.85 | PPARG (0.55) | PPARAPPARGFABP2SLC22A12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GLOBAVIR BIOSCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9315478-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| WO-2014087307-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES | KANDULA MAHESH (IN) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014083476-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIPID DISORDERS | KANDULA MAHESH (IN) | 2014-06-05 | — | — | WO | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | PPARA 1938/4885PPARG 1623/4885FABP2 427/4885 |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, IRS1, SLC5A2 | PPARA 1471/4885PPARG 942/4885FABP2 15/4885 |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | IDO2, IDO1, TDO2 | PPARA 2700/4885PPARG 1504/4885FABP2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.